<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626093</url>
  </required_header>
  <id_info>
    <org_study_id>CRD 388</org_study_id>
    <nct_id>NCT00626093</nct_id>
  </id_info>
  <brief_title>'Effect of CRT on Defibrillation Threshold Estimates' Study</brief_title>
  <official_title>Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective study is to evaluate the effect of cardiac resynchronization
      therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization
      therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation
      threshold (DFT) will decrease with 6 months of cardiac resynchronization therapy (CRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac Resynchronization Therapy (CRT) has emerged as a promising therapeutic addition in
      patients with drug refractory heart failure (HF). Along with providing relief of symptoms of
      HF, cardiac resynchronization therapy defibrillators (CRT-D) are used for the prevention of
      sudden cardiac death (SCD). Although there are concerns that the defibrillation threshold
      (DFT) estimates are elevated in the heart failure (HF) patient population due to lower LV
      ejection fraction (EF) and left ventricular (LV) dysfunction, there is paucity of data
      available to evaluate this theory.

      Recently, two different studies in a retrospective manner evaluated the energy requirements
      in patients receiving cardiac resynchronization therapy defibrillators (CRT-D). Burke et al
      analyzed DFTs in 50 patients each implanted with a cardiac resynchronization therapy
      defibrillators (CRT-D) device and an implantable cardioverter defibrillator (ICD). Although
      the ejection fraction (EF) in cardiac resynchronization therapy defibrillators (CRT- D) group
      was lower than the implantable cardioverter defibrillator (ICD) group, the mean
      defibrillation thresholds (DFTs) between the two groups were not significantly different
      (10.2 ± 6.1 J for the cardiac resynchronization therapy (CRT) group vs. 9.5 ± 5.0 J for the
      control group)14. In the ASSURE study, Doshi et al. showed that patients receiving cardiac
      resynchronization therapy defibrillators (CRT-D) devices do not have higher energy
      requirements when compared to patients receiving modern single or dual chamber implantable
      cardioverter defibrillators (ICDs). Although, there was a trend toward higher energy
      requirements found among patients with higher degrees of heart failure.

      Major cardiac resynchronization therapy (CRT) trials have showed that cardiac
      resynchronization therapy (CRT) therapy has positive effects on ejection fraction (EF) and
      the heart failure (HF) condition of the patient over time. But, there is no study that has
      evaluated the defibrillation thresholds (DFTs) in the heart failure (HF) patients over time
      of receiving cardiac resynchronization therapy (CRT). This information will help the
      clinicians decide if they need to perform more invasive procedures during device implant to
      lower DFTs in patients who do not meet the defibrillation safety margin or they should just
      wait over time for the CRT to reduce the defibrillation threshold (DFT). Also, there is no
      published data about the stability of defibrillation thresholds (DFTs) in heart failure (HF)
      patients over time. The results from this study will also help to clarify whether it is safe
      to never test the defibrillation thresholds (DFTs) post-implant in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Defibrillation Threshold Difference Obtained in Volts (V) Between Implant and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>All patients underwent defibrillation threshold testing at cardiac resynchronization therapy-defibrillator (CRT-D) implant and then at 6 months. The outcome measure is the difference in DFT (defibrillation threshold) in volts between implant and 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Defibrillation Threshold Difference Obtained in Joules (J)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Sudden Cardiac Death</condition>
  <arm_group>
    <arm_group_label>Cardiac Resynchronization Therapy - Defibrillator (CRT-D)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy - Defibrillator (CRT-D)</intervention_name>
    <description>Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).
Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions.</description>
    <arm_group_label>Cardiac Resynchronization Therapy - Defibrillator (CRT-D)</arm_group_label>
    <other_name>Epic HF,Atlas+ HF,Epic II HF,Atlas II HF,Promote CRT-D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient meets standard indications for a Cardiac Resynchronization Therapy -
             Defibrillator (CRT-D).

          -  Patient will be implanted with an FDA approved St Jude Medical (SJM) Cardiac
             Resynchronization Therapy - Defibrillator (CRT-D) and compatible defibrillation lead
             system.

          -  Patient is able to tolerate defibrillation threshold (DFT) testing.

          -  Patient is geographically stable and willing to comply with the required follow-up
             schedule.

          -  Patient has a life expectancy of greater than 6 months from the time of implant.

          -  Patient has stable heart failure (HF) medications at least one month prior to
             enrollment.

        Exclusion Criteria:

          -  Inability to successfully implant an intravascular lead Cardiac Resynchronization
             Therapy - Defibrillator (CRT-D) device. (i.e. exclude epicardial leads).

          -  Patient is getting his Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
             device replaced.

          -  Inability to successfully obtain the defibrillation threshold (DFT) at implant.

          -  Currently participating in a clinical trial that includes an active treatment arm or
             another data collection registry.

          -  Recent (within 24 hours) administration of Nesiritide™.

          -  Patient is on amiodarone (other antiarrhythmic agents known to affect defibrillation
             thresholds - DFTs) at the time of enrollment.

          -  Patient is pregnant.

          -  Patient is less than 18 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Hedayati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glendale Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gold, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Heart Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gold MR, Hedayati A, Alaeddini J, Payne JP, Bailin S, Sturdivant JJ, Pradhan S, Oza AL. Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm. 2011 Jul;8(7):1008-13. doi: 10.1016/j.hrthm.2011.02.006. Epub 2011 Feb 9.</citation>
    <PMID>21315841</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>July 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardiac Resynchronization Therapy - Defibrillators (CRT-D)</title>
          <description>All patients enrolled were indicated for a CRT-D.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>One of the required devices not implante</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Defibrillation Threshold Difference Obtained in Volts (V) Between Implant and 6 Months</title>
        <description>All patients underwent defibrillation threshold testing at cardiac resynchronization therapy-defibrillator (CRT-D) implant and then at 6 months. The outcome measure is the difference in DFT (defibrillation threshold) in volts between implant and 6 months.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
          </group>
        </group_list>
        <measure>
          <title>Defibrillation Threshold Difference Obtained in Volts (V) Between Implant and 6 Months</title>
          <description>All patients underwent defibrillation threshold testing at cardiac resynchronization therapy-defibrillator (CRT-D) implant and then at 6 months. The outcome measure is the difference in DFT (defibrillation threshold) in volts between implant and 6 months.</description>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="110.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Defibrillation Threshold Difference Obtained in Joules (J)</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
          </group>
        </group_list>
        <measure>
          <title>Defibrillation Threshold Difference Obtained in Joules (J)</title>
          <units>Joules</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Phrenic Nerve Stimulation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ashish Oza</name_or_title>
      <organization>St. Jude Medical</organization>
      <phone>818-493-3648</phone>
      <email>aoza@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

